Abstract
Although the concept of essential medicines is not new, the processes that lead to placement of these medicines on the World Health Organization Model List of Essential Medicines are not well understood. Here, we describe the process by which we added a class of drugs, statins, to the Model List to help combat the growing global epidemic of cardiovascular disease.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / economics
-
Drugs, Essential* / economics
-
Drugs, Essential* / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Models, Organizational*
-
World Health Organization / organization & administration*
Substances
-
Drugs, Essential
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors